NDC 73554-3111

Zynteglo

Betibeglogene Autotemcel

Zynteglo is a Intravenous Suspension in the Cellular Therapy category. It is labeled and distributed by Bluebird Bio, Inc.. The primary component is Betibeglogene Autotemcel.

Product ID73554-3111_f45a90ae-d8b0-43ce-a560-b906e33c9e23
NDC73554-3111
Product TypeCellular Therapy
Proprietary NameZynteglo
Generic NameBetibeglogene Autotemcel
Dosage FormSuspension
Route of AdministrationINTRAVENOUS
Marketing Start Date2022-08-17
Marketing CategoryBLA /
Application NumberBLA125717
Labeler Namebluebird bio, Inc.
Substance NameBETIBEGLOGENE AUTOTEMCEL
Active Ingredient Strength20000000 1/1
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 73554-3111-1

1 SUSPENSION in 1 BAG (73554-3111-1)
Marketing Start Date2022-08-17
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [Zynteglo]

Mark Image

Registration | Serial
Company
Trademark
Application Date
ZYNTEGLO
ZYNTEGLO
98405200 not registered Live/Pending
bluebird bio, Inc.
2024-02-14
ZYNTEGLO
ZYNTEGLO
98405197 not registered Live/Pending
bluebird bio, Inc.
2024-02-14
ZYNTEGLO
ZYNTEGLO
98405188 not registered Live/Pending
bluebird bio, Inc.
2024-02-14
ZYNTEGLO
ZYNTEGLO
97132197 not registered Live/Pending
bluebird bio, Inc.
2021-11-18
ZYNTEGLO
ZYNTEGLO
79271989 not registered Live/Pending
Bluebird Bio (UK) Ltd.
2019-10-10
ZYNTEGLO
ZYNTEGLO
79254523 5887775 Live/Registered
bluebird bio, Inc.
2019-01-30

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.